A comparison between triple and quadruple therapy efficacy in eradication of Helicobacter pylori in patients with dyspepsia

A comparison between triple and quadruple therapy efficacy in eradication of Helicobacter pylori in patients with dyspepsia referred to gastrointestinal clinic of Shohada-Ashayer and Shahid Rahimi hospitals of Khorramabad in 2015

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016012623736N2

Enrollment

321

Registered

2016-02-25

Start date

2016-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: The patients of Group C are placed under treatment for 7 days with the concomitant medication regimen. Intervention 2: The patients of groupA will be placed under treatment for 14 days

Treatment - Drugs

The patients of Group C are placed under treatment for 7 days with the concomitant medication regimen.

The patients of groupA will be placed under treatment for 14 days with a classic medication regimen (including omeprazole (20 mg / b.i.d) plus amoxicillin (1000 mg / b.i.d) and clarithromycin (500 mg

The patients of Group B are placed under treatment for 5 days with the concomitant medication regimen (including omeprazole (20 mg / bid) plus amoxicillin (1000 mg / bid), clarithromycin (500 mg / bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: The age of greater than 40 years; A positive family history of gastric cancer or patients who have signs and symptom sof gastric cancer; Also patients among whom, the symptoms have not ameliorated; despite a 6-week PPI therapy; and who have a positive biopsy. Exclusion criteria: Age less than 18 years; A positive history of allergic reaction to each of the medications used in this study; A history of eradication of Helicobacter pylori; A recent history (last month)of antibiotic therapy in each patient or pregnancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The eradication of Helicobacter pylori in group A. Timepoint: 6week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group A. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;The eradication of Helicobacter pylori in group A. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;The eradication of Helicobacter pylori in group C. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group B. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group C. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.	—

Measure

Time frame

The eradication of Helicobacter pylori in group A. Timepoint: 6week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group A. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;The eradication of Helicobacter pylori in group A. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;The eradication of Helicobacter pylori in group C. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group B. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group C. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.

—

Secondary

Measure	Time frame
The development of side effects of medications used in this study in any of the patients in Group A. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.;The development of side effects of medications used in this study in any of the patients in Group B. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.;The development of side effects of medications used in this study in any of the patients in Group C. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.	—

Measure

Time frame

The development of side effects of medications used in this study in any of the patients in Group A. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.;The development of side effects of medications used in this study in any of the patients in Group B. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.;The development of side effects of medications used in this study in any of the patients in Group C. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRouzbeh Yaghubi

Lorestan University Off Medical Sciences

yaghubiruzbeh@lums.ac.ir+98 66 3322 3004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026